Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Humble yeast sheds light on promising anti-cancer drug

19.10.2005


Research from the Journal of the National Cancer Institute



The humble yeast has revealed the molecular workings of an anti-cancer drug that stops the growth and spread of tumours in humans by starving their blood supply.

Until now, University of New South Wales scientists who developed the drug (GSAO) knew that it was lethal against endothelial cells but not why it had no direct impact on tumours themselves.


The new study reveals that endothelial cells lack the "transport protein" that tumours use to eject foreign molecules that invade their cell structure.

Endothelial cells are the building blocks of blood vessels. Cancer cells rely on blood vessel growth, known as angiogenesis, to grow and spread to other parts of the body.

"It’s very sexy science," says one the research authors, Professor Philip Hogg, a biochemist with the UNSW Centre for Vascular Research and the Children’s Cancer Institute Australia. "We now understand how an anti-cancer drug works in humans thanks to genetic studies using the humble yeast cell."

Published in today’s edition of the prestigious Journal of the National Cancer Institute, the study reveals how researchers "genetically fingerprinted" the transport protein by using genetically modified (mutant) yeast cells. The researchers used 4800 yeast mutants that represent every non-essential gene in the genome.

"The mutant yeast cells that were vulnerable to the drug lacked the protein that enables them to eject the drug across their cell membrane," says Professor Ian Dawes, a study co-author from the UNSW Ramaciotti Centre for Gene Function Analysis.

"Yeast cells that lacked the protein died, while those that had the protein didn’t," says Dawes. "That told us there was a specific gene encoding a protein that’s vital for a cell to protect itself against GSAO."

Once the researchers knew this they looked for and found a corresponding protein in humans, known as a multi-drug resistance associated protein (MRP).

"The presence of these transport proteins in tumours is one of the reasons that anti-cancer drugs such as chemotherapy medicines fail against cancer," says Professor Hogg.

"The reason that GSAO is effective is that it targets tumours indirectly by attacking the endothelial cells that lack this transport protein. So GSAO is lethal against tumours because it chokes the blood supply they rely on to grow and spread."

The amazing thing is that we’ve used the humble yeast, which is a less sophisticated cell than a human cell, to reveal the molecular secrets of the drug and how it works in humans.

The GSAO story

GSAO (glutathionarsenoxide) is an angiogenesis inhibitor drug that "starves" tumour cells by stopping them from making blood vessels -- known as angiogenesis - that tumours rely on to grow and spread. Professor Philip Hogg and Dr Neil Donoghue from the University of New South Wales invented GSAO in 1999.

Because all solid tumours of children and adults, such as cancer of the breast, prostate, colon, lung and brain rely on angiogenesis, a single anti-angiogenic drug should be effective against all tumour types. This is in contrast to chemotherapy drugs and radiotherapy that are often effective only against certain tumour types. Also, because GSAO is not a conventional "cytotoxic" drug that poisons cancer cells, it does not cause unpleasant side effects such as nausea and hair loss.

Small blood vessels consist primarily of endothelial cells that line their interior. They are genetically stable, in contrast to tumour cells that are inherently unstable. Most tumour cells have a propensity for mutation and genetic diversity, and are therefore likely to produce drug resistant cells. The genetic stability of endothelial cells suggests that anti-angiogenic drugs that target the stimulated endothelial cells in tumours will be less prone to resistance than the chemotherapeutic agents that target the tumour cells.

While GSAO would not "cure" people of the cancer, it should stop most types of tumours in their tracks. This means that the focus of cancer treatment and research could move away from curing the disease to one of managing it on a life-long basis, such as diabetes.

GSAO will be first tested in cancer patients in 2006.

Prof. Philip Hogg | EurekAlert!
Further information:
http://www.unsw.edu.au

More articles from Life Sciences:

nachricht What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>